Cannabinoids in the spotlight: DSM and Brains Bioceutical partner to support early-stage cannabinoid-based drug development
30 Jun 2021 | 4 min
The science behind cannabidiol (CBD) is growing rapidly – with the ingredient demonstrating positive medical potential in a wide variety of areas, including CNS (central nervous system) diseases, pain disorders, cancer and more. This is creating a myriad of opportunities for innovation across the pharmaceutical industry, as well as new product developments that will support global patient health.
To help customers realize the full potential of CBD – and inspire the creation of bespoke, purpose-led drug products – we’ve created an innovation platform that facilitates early-stage drug development and novel scientific discoveries in this new and exciting field. Our offering includes:
The CBD market is full of promise. Download our brochure to unlock the potential of CBD-based innovation and learn more about how DSM can help you enter the market with confidence.
This whitepaper takes a deep dive into the promising therapeutic potential of cannabinoids in early-stage drug development, exploring the latest science-based benefits and innovation opportunities to develop next generation drug products in the pharmaceutical space.
This whitepaper explores the challenges surrounding the oral bioavailability of cannabidiol and the benefits of using lipid-based systems in your formulation. Unlock novel opportunities in the cannabidiol space.
The CBD-based drug market is growing rapidly, powered by increasing scientific research indicating the positive therapeutic potential of cannabinoid actives, mostly cannabidiol (CBD) in a wide variety of health areas including CNS (central nervous system) diseases, pain disorders, cancer and more. Watch our video to learn how partnering with DSM can help you to explore CBD-based innovation opportunities.
Watch our latest webinar held in partnership with Manufacturing Chemist and join Professor José Alexandre de Souza Crippa, Department of Neurosciences and Behaviour, University of São Paulo, Brazil, and Dr Mariana Coelho, Clinical Project Scientist at DSM, as they discuss the latest science and promising research into whether cannabidiol is a potential therapy to treat patients suffering from mental health conditions.
Tune in to our new expert-led webinar series, brought to you in partnership with Brains Bioceutical, to discover the latest and greatest science surrounding cannabidiol in medical use. Joined by Dr. David (Dedi) Meiri, Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC), and Renata Heusser Jungman, President of the Swiss Dravet-Syndrome Association, the first session explores the fast-evolving research on the endocannabinoid system and its practical applications for disease treatment.
The CBD market is full of promise, but it takes more than ingredients to enter the CBD market with confidence. It takes a partner.
Together with Brains Bioceutical – a pioneer in the CBD API market – we’re helping our customers explore the potential of CBD-based pharmaceuticals. Our newly launched innovation platform enables agile, early-stage drug development to deliver value-added CBD-based products in a rapidly evolving market. We have the core competencies, combined with a deep understanding of patient and customer needs, to help brands enter the CBD market with confidence. With more than 70 years of experience in producing and securing the supply of APIs, we bring passion, unique innovation expertise and support in managing the market entry registration process.
Together, let’s deliver CBD-based pharmaceuticals with purpose. Connect with one of our experts today.
CBD is set to disrupt the dietary supplement category, driven by strong consumer interest in the ingredient’s possible benefits for immunity, stress, mood, sleep and more. Learn about our CBD offering for the nutrition market and how we’re supporting customers develop health benefit-driven products – from concept to consumer – with market-ready and premix solutions.
30 Jun 2021 | 4 min